A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in these patient populations.

开始日期2024-09-01

申办/合作机构

Endeavor BioMedicines, Inc初创企业

NCT05817240 / Completed临床1期

A Phase 1, Single-Center, Fixed Sequence, Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary fibrosis) when the two compounds are dosed together in healthy subjects. Participants in this study will receive ENV-101 and/or nintedanib on various days throughout a 10-day period during which they will reside at the clinical trial site.

开始日期2023-05-03

申办/合作机构

Endeavor BioMedicines, Inc初创企业

NCT04968574 / Completed临床2期

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of treatment. Following treatment, subjects will be observed for an additional 6 weeks.

开始日期2021-08-26

申办/合作机构

Endeavor BioMedicines, Inc初创企业

100 项与 Taladegib 相关的临床结果

登录后查看更多信息

100 项与 Taladegib 相关的转化医学

登录后查看更多信息

100 项与 Taladegib 相关的专利（医药）

登录后查看更多信息

项与 Taladegib 相关的文献（医药）

2021-08-01·Investigational new drugs3区 · 医学

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors

3区 · 医学

Article

作者: Pant, Shubham ; Yuen, Eunice ; Benhadji, Karim A ; Merchan, Jaime ; Yu, Danni ; Oakley, Gerard ; Azaro, Analia ; Tap, William D ; Cassier, Philippe A ; Anderson, Bailey ; Italiano, Antoine ; Massard, Christophe

Notch signaling plays an important role in development and tissue homeostasis. Deregulation of Notch signaling has been implicated in multiple malignancies. Crenigacestat (LY3039478), a potent Notch inhibitor, decreases Notch signaling and its downstream biologic effects. I6F-MC-JJCD was a multicenter, nonrandomized, open-label, Phase 1b study with 5 separate, parallel dose-escalations in patients with advanced or metastatic cancer from a variety of solid tumors, followed by a dose-confirmation phase in prespecified tumor types. This manuscript reports on 3 of 5 groups. The primary objective was to determine the recommended Phase 2 dose of crenigacestat in combination with other anticancer agents (taladegib, LY3023414 [dual inhibitor of phosphoinositide 3-kinase; mechanistic target of rapamycin], or abemaciclib). Secondary objectives included evaluation of safety, tolerability, efficacy, and pharmacokinetics. Patients (N = 63) received treatment between November 2016 and July 2019. Dose-limiting toxicities occurred in 12 patients, mostly gastrointestinal (diarrhea, nausea, vomiting). The maximum-tolerated dose of crenigacestat was 25 mg in Part B (LY3023414), 50 mg in Part C (abemaciclib), and not established in Part A (taladegib) due to toxicities. Patients had at least 1 adverse event (AE) and 75.0-82.6% were ≥ Grade 3 all-causality AEs. No patient had complete or partial response. Disease control rates were 18.8% (Part B) and 26.1% (Part C). The study was terminated before dose confirmation cohorts were triggered. This study demonstrated that crenigacestat combined with different anticancer agents (taladegib, LY3023414, or abemaciclib) was poorly tolerated, leading to lowered dosing and disappointing clinical activity in patients with advanced or metastatic solid tumors. NCT02784795 and date of registration: May 27, 2016.

2020-03-01·Bioorganic & medicinal chemistry

Design, synthesis and biological evaluation of anthranilamide derivatives as potent SMO inhibitors

Article

作者: Xu, Yungen ; Zhang, Wanwan ; Zhang, Jing-Jing ; Ji, Dezhong

A series of anthranilamide derivatives were designed and synthesized as novel smoothened (SMO) inhibitors based on the SMO inhibitor taladegib (LY2940680), which can also inhibit the SMO-D473H mutant, via a ring-opening strategy. The phthalazine core in LY2940680 was replaced with anthranilamide, which retained the inhibitory activity towards the hedgehog (Hh) signaling pathway as evidenced by a dual luciferase reporter gene assay. Compound 12a displayed the best inhibitory activity against the Hh signaling pathway with IC₅₀ value of 34.09 nM, and exhibited better proliferation inhibitory activity towards the Daoy cell line (IC₅₀ = 0.48 μM) than LY2940680 (IC₅₀ = 0.79 μM).

2020-03-01·Cutis4区 · 医学

Emerging noninvasive treatments of nonmelanoma skin cancers.

4区 · 医学

Article

作者: Psomadakis, Corinna Eleni ; Markowitz, Orit ; Paka, Pavan ; Marghoob, Nadeem ; Tongdee, Emily

Nonmelanoma skin cancer (NMSC) is the most common malignancy worldwide, and the incidence continues to increase. Originally, treatment options for NMSCs largely relied on destructive and surgical methods. Basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) commonly are treated with cryosurgery, electrodesiccation and curettage, or more definitive surgical options. Over time, topical agents such as 5-fluorouracil, imiquimod, ingenol mebutate, and various forms of aminolevulinic acid (ALA) for photodynamic therapy (PDT) were included for superficial lesions as well as field treatment. The development of oral hedgehog (Hh) inhibitors such as vismodegib offered a promising alternative to patients with advanced disease. Each treatment has its own specific indications and side effects, thus there is always room for novel therapeutic approaches. We review new and potential treatments for NMSCs since 2018 including topical sonidegib, cemiplimab, taladegib, posaconazole, radiation therapy (RT), combination RT with vismodegib, PDT, and laser therapies.

项与 Taladegib 相关的新闻（医药）

2024-06-30

·Pharma CMC

130亿元！21家ADC企业获得融资（2024 H1）

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。目前ADC药物已成为最热门的创新药赛道之一，国内已有多家医药领域企业布局该赛道，各大企业纷纷利用融资来加大自身发展优势。2024年上半年，国内外已有21家ADC药企迎来了新一轮融资进展，融资总额约130亿元。小编汇总如下： 01 拓济医药:超亿元Pre-A轮融资近日，国内领先的双抗ADC公司拓济医药（Phrontline Biopharma）宣布完成超亿元Pre-A轮融资，由德诚资本独家投资。本轮融资后，拓济将加大研发投入力度，加快多个临床前管线推进，升级自有技术平台，向着“成为全球领先的制药公司”愿景加速前进。针对现有单抗ADC成药性痛点，拓济医药制定了高度前瞻性、差异化的管线策略，设计了全球首创的双靶点ADC、dual-linker-payload ADC等分子管线，带来更大的治疗窗并解决毒素耐药、低表达人群失效等单抗ADC面临的问题。目前公司多个双抗ADC管线正在快速推进。其核心研发项目TJ101与同靶点单抗ADC相比，在多种临床前肿瘤模型中体现出更优的肿瘤选择性和生长抑制效果。其潜在适应症包括肺癌、头颈癌等多种实体瘤。 02 InduPro:8500元美元A轮融资 2024年6月13日，InduPro宣布已经完成了8500万美元的A轮融资。本轮融资由the Column Group和Vida Ventures联合领投，其他投资者包括MRL Ventures Fund（默沙东的风险投资基金）、Emerson Collective和Euclidean Capital。这笔资金将推动InduPro基于共同靶向对的邻近性，将其首个预期临床候选产品从临床前开发推进到2025年第四季度的1期临床试验预期IND申报。此外，资金还将用于新的双特异性抗体和抗体偶联药物（ADC）管线的开发，这些管线利用蛋白质邻近性来鉴定新的肿瘤选择性靶标对。 InduPro的双特异性ADC项目使用其TAPA治疗方法，根据发现的共靶对的邻近性，特异性靶向癌症组织。在“免疫突触调节”方法中，多特异性抗体针对靶点，在治疗自身免疫性疾病或免疫肿瘤学时，其诱导的邻近性募集并激活免疫细胞表面的蛋白质。这轮融资的成功完成，不仅为InduPro提供了推进其创新药物开发的动力，也体现了投资者对于公司研发实力和基于蛋白质邻近性新药开发潜力的信心。随着临床项目的不断深入，InduPro有望为癌症和自身免疫性疾病患者带来新的治疗选择。 03 Adcytherix:3000万欧元种子轮融资 6月11日，法国马赛，Adcytherix SAS宣布完成3000万欧元（约3200万美元）的种子轮融资，用于开发新型抗体偶联物药物（ADC），用于治疗癌症等高需求疾病。种子轮融资由Pontifax领投，Pureos Bioventures、RA Capital Management和Dawn Biopharma（KKR控制的平台）跟投。管理层也参与了种子轮跟投。种子轮融资由Pontifax领投，Pureos Bioventures、RA Capital Management和Dawn Biopharma（KKR控制的平台）跟投。管理层也参与了种子轮跟投。 04 普灵生物:1700万元A2轮增资 2024年5月31日，复星医药发布控股企业苏州星未来基金、第三方红树林投资与普灵生物及其创始股东等共同签订《A2轮增资协议》，苏州星未来基金、红树林投资拟现金出资共计人民币 1,683.3333 万元认缴普灵生物新增注册资本合计人民币 1,230,506.79 元，其中：苏州星未来基金拟现金出资人民币 750 万元认缴新增注册资本人民币 548,245.61 元（即本次投资）。普灵生物主要从事第四代抗体偶联药物（ADC）领域的研发，依托其自主搭建的新一代药物偶联递送技术平台，可以针对不同靶点筛选适配的连接子-毒素系统，主要面向肿瘤治疗领域开展传统及新型 ADC 药物管线（包括纳米抗体ADC 、免疫调节类ADC 、抗体偶联类AOC）的开发。截至 2024年5月31日，普灵生物推进中的4条抗体偶联药物（ADC）管线均处于临床前研究阶段，目标适应症包括肺癌、卵巢癌等；另有1条抗体核酸偶联药物（AOC）管线处于概念验证阶段。 05 Pheon:1.2亿美元B轮融资 2024年5月21日，ADC公司Pheon Therapeutics（Pheon）宣布完成1.2亿美元（约8.68亿元）的B轮融资，本轮融资将使Pheon的业务持续到2027年，并支持三款ADC的早期临床测试。此次融资由TCGX领投，新投资者BVF Partners、Lightspeed和Perceptive Advisors以及现有投资者Atlas Venture、Brandon Capital、Forbion 和 Research Corporation Technologies参投。作为融资的一部分，TCGX的执行合伙人Cariad Chester 将加入董事会。新的融资将用于进一步推动Pheon的差异化ADC产品管线通过临床概念验证。Pheon的三项主要资产针对的是一个未公开的新靶点，该靶点在多种实体瘤中高度过表达。第一个项目利用DAR8拓扑异构酶-1抑制剂连接载体，展示了前所未有的临床前治疗指数，而接下来的两个ADC则利用其他连接载体技术挖掘这一靶点的广泛潜力。公司预计在 2024 年启动首个1期临床试验，并迅速向剂量扩展队列迈进。这笔资金还将使Pheon的一套内部技术平台能够扩展，以生成优化的ADC结构。 06 Endeavor:1.325亿美元C轮融资 4月24日，Endeavor BioMedicines宣布成功完成了1.325亿美元的C轮融资。Endeavor 将利用本轮融资推进ENV-101的临床开发，ENV-101是其用于治疗特发性肺纤维化 (IPF) 和进行性肺纤维化 (PPF) 的主要候选药物；并通过临床概念验证研究推进ENV-501，一种用于治疗HER3阳性实体瘤的人类表皮生长因子3 (HER3) 抗体-药物偶联物 (ADC)。本轮融资由Matrix Capital Management旗下的AyurMaya领投。新投资者包括Fidelity Management & Research Company、Invus、SymBiosis、Velosity Capital和Woodline Partners。现有投资者包括abrdn管理的基金、Ally Bridge Group、Avidity Partners、Eckuity Capital、Longitude Capital、Omega Funds、Perceptive Advisors、Piper Heartland Healthcare Capital、Silver Arch Bio和T. Rowe Price Associates也提供了强有力的支持。 07 TORL:1.58亿美元B2轮融资 4月10日，专注于开发癌症治疗的新生物制剂的生物制药公司TORL BioTherapeutics宣布完成1.58亿美元的B2轮融资。本轮融资由Deep Track Capital领投，RA Capital Management、Perceptive Advisors和Avidity Partners在内的生物技术投资者以及所有现有生物技术投资者的跟投。融资资金将用于继续ADC药物TORL-1-23的临床开发，推进TORL-1-23项目到第一阶段，以及将于今年下半年开始的关键第二阶段。这项2期临床试验旨在促进TORL-1-23作为CLDN 6+铂类耐药卵巢癌患者的新疗法的监管审查和潜在批准。所得资金还将用于推进TORL-2-307正在进行的一期研究，TTORL-2-307是一种用于治疗CLDN 18.2+实体瘤的临床阶段ADC药物，TORL-3-600是一种CDH17+结直肠癌ADC 08 BrickBio:未公布融资金额 3月18日，BrickBio获得了三星风险投资公司的投资。该公司打算利用这笔资金支持其蛋白质工程技术和临床前资产的进一步开发和进步。这项最新投资反映了三星致力于发现和探索生物制药领域的新机遇，以满足尚未得到满足的治疗需求。三星的子公司将与BrickBio合作，利用BrickBio专有的蛋白质工程技术评估、生产和开发先进的分子和疗法，用于ADC、AAV基因疗法和其他药物。 BrickBio 是一家生物技术公司，由首席执行官John Boyce 领导，提供位点特异性和位点选择性平台，涵盖原核和真核表达系统，能够开发具有增强特性的独特生物制剂和蛋白质疗法，包括改善半衰期、剂量和疗效。借助一套生物共轭处理工具，它可以优化任何共轭物。该公司正在扩大其治疗项目，包括ADC、双特异性共轭物和新型支架。往期文章：13家ADC药企获得超80亿元融资（2024 Q1）国内125家ADC企业盘点参考资料：各公司公告

抗体药物偶联物临床申请临床1期

2024-05-20

·药明康德

治疗DMD等肌肉疾病的潜在“first-in-class”抗体偶联ASO疗法，改善肺纤维化的小分子疗法……

▎药明康德内容团队编辑Dyne Therapeutics公布抗体偶联反义寡核苷酸疗法积极临床结果Dyne Therapeutics今日公布了分别用于治疗强直性肌营养不良1型（DM1）和杜氏肌营养不良（DMD）的抗体偶联反义寡核苷酸（ASO）疗法DYNE-101和DYNE-251的积极1/2期临床试验结果。该公司表示，这些结果继续支持使用加速批准通道开发这两款ASO疗法。在1/2期临床试验ACHIEVE中，DYNE-101（5.4 mg/kg）在第3个月时表现出剂量依赖性剪接校正，剪接校正比例达到27%。此外，DYNE-101改善患者的肌肉强直、肌肉力量以及多种患者报告的功能性和疲惫指标。在1/2期临床试验DELIVER中，DYNE-251（10 mg/kg）在6个月时将抗肌萎缩蛋白（dystrophin）的表达水平提高到接受标准治疗患者的10倍。多种功能性检测也显示出接受DYNE-251治疗患者的功能改善。Dyne Therapeutics的抗体偶联ASO由靶向肌肉表面表达的转铁蛋白受体1（TfR1）的抗体和ASO偶联生成。这一技术旨在实现靶向肌肉组织的ASO递送。▲抗体偶联ASO平台的示意图（图片来源：Dyne Therapeutics公司官网）改善肺功能并逆转肺纤维化，小分子疗法2期临床结果积极Endeavor BioMedicines公司日前宣布在研疗法ENV-101在治疗特发性肺纤维化（IPF）的2a期临床试验中获得积极结果。12周后，接受ENV-101治疗的IPF患者的肺功能和总肺容量（TLC）获得显著改善，多个量化检测肺纤维化的指标得到逆转。新闻稿指出，这些数据支持ENV-101作为首个改变疾病进程的IPF疗法。试验数据显示，接受ENV-101治疗的患者在试验的12周内肺功能显著改善，预测用力肺活量百分比（ppFVC）从基线提高了1.9%，而安慰剂组患者的ppFVC平均下降了1.3%（P=0.035）。接受ENV-101治疗的患者在12周时TLC平均增加了200 mL，而安慰剂组患者平均下降了56 mL（P=0.005）。在接受ENV-101治疗的患者中，80%患者的TLC增加，而接受安慰剂的患者中有70%患者的TLC下降。ENV-101旨在通过抑制过度激活的Hedgehog（Hh）信号通路来提高患者的肺功能并逆转患者肺部的纤维化。Hh通路是一个伤口愈合信号通路，当其异常活跃时，会导致肺部形成瘢痕组织。现有疗法只能稍微减缓肺功能下降，但并未解决疾病根源，且由于耐受性问题，大多数患者难以长期使用。ENV-101提供了一种新的方法，可能中止甚至逆转纤维化进程。Vicore Pharma小分子疗法显著改善IPF患者肺功能Vicore Pharma日前发布了在研血管紧张素II型受体激动剂buloxibutid治疗初治IPF患者的2a期临床试验的最终数据。该试验在主要和次要终点上均显示出积极结果，表现出卓越的安全性、耐受性和疗效。在36周的治疗期间，buloxibutid改善了基于用力肺活量（FVC）检测的肺功能。未经治疗的患者在36周内FVC大约下降180 mL。在AIR试验中，患者的FVC从基线到第36周平均增加了216 mL，比未经治疗的患者高出近400 mL（n=28，p<0.001）。▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料：[1] Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints. Retrieved May 20, 2024, from https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-clinical-data-achieve-trial-dyne[2] New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines’ ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis. Retrieved May 20, 2024, from https://www.businesswire.com/news/home/20240519406386/en/[3] Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis. Retrieved May 20, 2024, from https://vicorepharma.com/mfn_news/vicore-announces-positive-final-results-from-the-phase-2a-air-trial-demonstrating-buloxibutid-improves-lung-function-over-36-weeks-in-patients-with-idiopathic-pulmonary-fibrosis/免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床结果临床2期寡核苷酸加速审批

2024-05-20

·FierceBiotech

Taking on pharma giants, Endeavor links IPF drug to improved lung function in phase 2

Endeavor BioMedicines is preparing to run another study with a global phase 2b idiopathic pulmonary fibrosis cohort. Endeavor BioMedicines has linked its Hedgehog inhibitor to improved lung function in a phase 2a idiopathic pulmonary fibrosis (IPF) study, sending a sonic pulse through a sector currently dominated by drugs that only slow the decline of the disease. Boehringer Ingelheim and Roche respectively turned Ofev and Esbriet into blockbusters on the back of evidence they can slow the decline in lung function. In one pivotal Ofev trial, lung function worsened (PDF) in 70% of patients who received the Boehringer drug for 52 weeks. The Esbriet label features (PDF) data from a pivotal study in which the lung function of 77% of patients taking the drug deteriorated. While Ofev and Esbriet became blockbusters by slowing the decline of IPF patients, Endeavor wants to supplant the incumbents by reversing the disease. The phase 2a trial provides early clinical evidence that the biotech may be able to achieve that goal by targeting a type of fibroblast thought to drive IPF. Investigators randomized 41 people with IPF to receive ENV-101 or placebo once daily. After 12 weeks, Endeavor saw a 1.9% mean improvement in a measure of lung function, namely percent predicted forced vital capacity (ppFVC) from baseline. PpFVC fell 1.3% in the placebo arm, causing the study to hit its primary endpoint with a p-value of 0.035. Endeavor shared other evidence that ENV-101 may change the course of the disease. Total lung capacity (TLC) increased 200 mL on average in the treatment group, compared to a 56-mL decline in the placebo arm. TLC increased in 80% of patients on ENV-101 and decreased in 70% of people taking placebo. The biotech also used imaging to assess lung fibrosis. Quantitative interstitial lung disease, a measure of lung fibrosis and other attributes, fell 9.4% in the ENV-101 group while rising 1.1% in the placebo arm. Measures of quantitative lung fibrosis and ground glass also favored the study drug. On the safety front, no patients on ENV-101 had treatment-related serious adverse events, grade 3 or 4 adverse events, or clinically meaningful safety findings on laboratory analyses and other assessments. But some mild to moderate adverse events were common, with between 43% and 57% of participants having alterations in taste, hair loss or muscle spasms while taking the study drug. Hair loss, known medically as alopecia, is mentioned in the Ofev label but only affected 0.8% of patients. Similarly, dysgeusia, the medical term for alterations in taste, features on the Esbriet label because it affected 6% of recipients of the drug. Endeavor is preparing to run another study with a global phase 2b IPF cohort and a parallel phase 2 cohort of individuals with progressive pulmonary fibrosis.

临床2期临床结果

100 项与 Taladegib 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10671	-	-	DB12550

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
进行性肺纤维化	临床2期	美国	Endeavor BioMedicines, Inc初创企业	2024-09-01
进行性肺纤维化	临床2期	澳大利亚	Endeavor BioMedicines, Inc初创企业	2024-09-01
进行性肺纤维化	临床2期	奥地利	Endeavor BioMedicines, Inc初创企业	2024-09-01
进行性肺纤维化	临床2期	加拿大	Endeavor BioMedicines, Inc初创企业	2024-09-01
进行性肺纤维化	临床2期	德国	Endeavor BioMedicines, Inc初创企业	2024-09-01
进行性肺纤维化	临床2期	爱尔兰	Endeavor BioMedicines, Inc初创企业	2024-09-01
进行性肺纤维化	临床2期	马来西亚	Endeavor BioMedicines, Inc初创企业	2024-09-01
进行性肺纤维化	临床2期	墨西哥	Endeavor BioMedicines, Inc初创企业	2024-09-01
进行性肺纤维化	临床2期	韩国	Endeavor BioMedicines, Inc初创企业	2024-09-01
进行性肺纤维化	临床2期	瑞士	Endeavor BioMedicines, Inc初创企业	2024-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04968574 (ENV-IPF-101, ATS2024) 人工标引	临床2期	特发性肺纤维化	41	ENV-101	繭鏇鑰簾壓齋觸願醖顧(蓋糧鬱構窪鏇蓋積鏇齋) = The most common ENV-101-related adverse events were dysgeusia (alterations in taste; 57%), alopecia (52%) and muscle spasms (43%), which were all mild to moderate in severity. 膚餘鹽簾鬱鹹範選繭選 (鏇鹹鹽蓋範鏇艱齋糧蓋 ) 更多	积极	2024-05-19
NCT02530437 (CTgov)	临床1/2期	食管腺癌 \| 胃食管交界处癌 \| 胃食管交界处腺癌	7	TALADEGIB	鬱廠鹹簾鏇選憲糧糧鏇(觸築繭衊鹹襯遞築醖顧) = 鹽顧製構齋鬱獵齋製夢築憲鹽膚簾糧齋遞膚鬱 (願鏇築淵夢壓憲淵廠鹹, 餘簾選壓膚選繭膚夢蓋 ~ 廠夢築艱顧壓夢廠選獵) 更多	-	2023-07-10
NCT02784795 (I6F-MC-JJCD, Pubmed \| Invest New Drugs)	临床1期	转移性实体瘤	63	Crenigacestat + Taladegib	製膚範願觸膚膚衊蓋積(鬱壓膚鏇齋蓋淵顧繭襯) = 網簾製顧夢鬱醖選醖糧窪廠願觸網襯築鬱鹽製 (繭憲遞簾齋鏇鹽醖鹽遞 )	不佳	2021-03-08
NCT02784795 (I6F-MC-JJCD, Pubmed \| Invest New Drugs)	临床1期	转移性实体瘤	63	Crenigacestat + LY3023414	製膚範願觸膚膚衊蓋積(鬱壓膚鏇齋蓋淵顧繭襯) = 鏇觸獵憲淵餘壓願觸選窪廠願觸網襯築鬱鹽製 (繭憲遞簾齋鏇鹽醖鹽遞 ) 更多	不佳	2021-03-08
NCT01919398 (CTgov)	临床1期	晚期恶性实体瘤 \| 晚期癌症	19	LY2940680 (Cohort 1: 100 mg LY2940680)	範製蓋鑰鏇糧製鹽獵築(蓋艱築獵鹹壓餘餘觸艱) = 構築淵壓餘積齋廠壓簾鑰簾鏇觸齋鬱範蓋鬱簾 (獵鑰製襯遞鬱淵繭獵窪, 憲構餘簾憲鑰獵窪蓋齋 ~ 鑰選淵憲糧觸廠築顧襯) 更多	-	2019-09-11
NCT01919398 (CTgov)	临床1期	晚期恶性实体瘤 \| 晚期癌症	19	LY2940680 (Cohort 2: 200 mg LY2940680)	範製蓋鑰鏇糧製鹽獵築(蓋艱築獵鹹壓餘餘觸艱) = 淵襯醖襯餘鑰憲選憲淵鑰簾鏇觸齋鬱範蓋鬱簾 (獵鑰製襯遞鬱淵繭獵窪, 廠糧蓋積窪構衊鹹夢淵 ~ 醖獵網憲醖遞窪願鹹築) 更多	-	2019-09-11
NCT01746745 (CTgov)	临床1期	-	6	[^14C]-LY2940680	蓋壓鹹鏇衊觸夢鏇襯選(淵鹽觸憲鑰醖顧築獵襯) = 鏇廠網淵獵鬱餘繭壓鹽顧鏇鬱鬱淵憲顧齋獵襯 (願糧簾襯廠鏇窪餘糧獵, 積廠遞網廠觸襯鹹選淵 ~ 顧壓艱遞襯製衊顧鹽廠) 更多	-	2019-07-22
NCT01919398 (Pubmed \| Invest New Drugs) 人工标引	临床1期	HR阳性/HER2低表达实体瘤	19	taladegib	夢鬱觸網鹽鏇蓋醖齋簾(衊艱繭憲糧廠淵簾顧醖) = No dose-limiting toxicities (DLTs) were observed at doses of 100 mg or 200 mg; 3 of the 9 patients evaluable for DLTs at the 400 mg dose level experienced DLTs (thrombocytopenia: 1; decreased appetite: 2) 簾鹹醖簾鏇糧鹹壓鏇範 (簾鏇鑰鏇鑰憲廠製顧糧 ) 更多	积极	2018-08-01
NCT01226485 (Pubmed \| Clin Cancer Res) 人工标引	临床1期	基底细胞癌 \| 晚期癌症	84	LY2940680	積餘鏇築選構淵蓋醖窪(獵鬱網構膚網顧選積膚) = 簾窪糧願蓋鬱積獵鏇製窪餘範窪築醖範窪衊築 (鏇獵簾願鏇鹽鬱顧壓膚 ) 更多	积极	2018-05-01